A single dose of life-saving MSC therapy requires billions of cells. To reach this clinical benchmark, traditional workflows that use 2D cell culture methods require hundreds to thousands of individual culture vessels in an expansion seed train. Furthermore, the 2D process is comprised of several manual operations, including open handling steps, which increases the risk of contamination. Thus, scale-up strategies using microcarrier-based 3D suspension processes are significantly more sustainable, efficient and cost-effective. This webinar showcases the successful transition and scale-up from a 2D culture process to 3D suspension-based platform.

Watch now to learn about:

• Streamlining expansion seed trains while minimizing contamination risk
• Characterizing MSCs for phenotypic and functional therapeutically relevant critical quality attributes (CQAs)
• Decreasing development time and cost of goods sold (COGS)